- Home
- CNTB vs PMN Comparison
CNTB vs PMN Comparison
Compare CNTB & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | PMN |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.7M | 115.5M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CNTB | PMN |
|---|---|---|
| Price | $2.39 | $10.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $8.67 | ★ $42.67 |
| AVG Volume (30 Days) | ★ 154.0K | 26.0K |
| Earning Date | 08-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $64,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.73 | $0.29 |
| 52 Week High | $3.82 | $27.40 |
Technical Indicators
Market Signals| Indicator | CNTB | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 46.21 |
| Support Level | $2.30 | $10.55 |
| Resistance Level | $2.67 | $13.80 |
| Average True Range (ATR) | 0.18 | 0.50 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 31.44 | 63.84 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.